Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Executive Summary
Current European-based specialty pharma companies are in transition, awaiting key regulatory decisions, overhauling management or engaged in M&A. Their fates will help answer a critical question: under what circumstances can this class of companies continue to deliver long term growth as independent entities?
You may also be interested in...
With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus
U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Japan's largest drug maker, Takeda Pharmaceuticals Co. Ltd., may be close to buying private-equity owned Nycomed AS, based in Switzerland, for about $12 billion
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
The deal, if confirmed, would boost Takeda's European and emerging markets presence, providing an additional €3.2 billion in revenues to help offset forthcoming patent expiries.